Resverlogix Corp. was founded in 2001 by Donald McCaffrey and Norman Wong. In 2005, Resverlogix commenced trading on the TSX under the symbol RVX. Lead drug apabetalone was discovered in 2006 and today it has progressed from preclinical studies to a Phase 3 clinical trial. With the discovery of apabetalone, Resverlogix is pioneering the landscape of epigenetics. Apabetalone is the most advanced epigenetic therapeutic in development for high-risk cardiovascular disease, diabetes mellitus and chronic kidney disease.